Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Atezolizumab in combination with Bevacizumab, Carboplatin, and Paclitaxel in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tecentriq (atezolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.